Profound Medical (TSE:PRN) has released an update.
Don't Miss our Black Friday Offers:
- Unlock your investing potential with TipRanks Premium - Now At 40% OFF!
- Make smarter investments with weekly expert stock picks from the Smart Investor Newsletter
Profound Medical has appointed Tom Tamberrino as Chief Commercial Officer to drive the widespread adoption of its TULSA technology, a promising treatment for prostate disease. This strategic move comes ahead of anticipated changes in reimbursement codes that could significantly boost the company’s market position.
For further insights into TSE:PRN stock, check out TipRanks’ Stock Analysis page.
